{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:58:16Z","timestamp":1778536696434,"version":"3.51.4"},"reference-count":53,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0262","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:24:09Z","timestamp":1525238649000},"source":"Crossref","is-referenced-by-count":2,"title":["The Indications for Allogeneic Stem Cell Transplantation in Myeloid Malignancies"],"prefix":"10.3238","author":[{"given":"Lutz P.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"key":"10.3238\/arztebl.2015.0262_ref1","doi-asserted-by":"crossref","unstructured":"Visser O, Trama A, Maynadie M, et al.: Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012; 48: 3257\u201366","DOI":"10.1016\/j.ejca.2012.05.024"},{"key":"10.3238\/arztebl.2015.0262_ref2","doi-asserted-by":"crossref","unstructured":"Wolff D, Bertz H, Greinix H, et al.: The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch Arztebl Int 2011; 108: 732\u201340","DOI":"10.3238\/arztebl.2011.0732"},{"key":"10.3238\/arztebl.2015.0262_ref3","doi-asserted-by":"crossref","unstructured":"Ljungman P, Bregni M, Brune M, et al.: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219\u201334","DOI":"10.1038\/bmt.2009.141"},{"key":"10.3238\/arztebl.2015.0262_ref4","unstructured":"Deutsche Arbeitsgemeinschaft f\u00fcr Knochenmark- und Blutstammzelltransplantation e. V. (DAG-KBT): Indikationsliste DAG-KBT. www.dag-kbt.de\/content\/public\/Indikationsliste-DAG.pdf (last accessed on 1 March 2015)."},{"key":"10.3238\/arztebl.2015.0262_ref5","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Mittermuller J, Clemm C, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462\u20135","DOI":"10.1182\/blood.V76.12.2462.2462"},{"key":"10.3238\/arztebl.2015.0262_ref6","doi-asserted-by":"crossref","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, et al.: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u201361","DOI":"10.1038\/leu.2009.38"},{"key":"10.3238\/arztebl.2015.0262_ref7","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G, et al.: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u201384","DOI":"10.1182\/blood-2013-05-501569"},{"key":"10.3238\/arztebl.2015.0262_ref8","unstructured":"Hochhaus A, Baerlocher G, Br\u00fcmmendorf TH, et al.: Chronische myeloische Leuk\u00e4mie (CML). Leitlinie. www.dgho-onkopedia.de\/de\/onkopedia\/leitlinien\/cml (last accessed on 1 March 2015)."},{"key":"10.3238\/arztebl.2015.0262_ref9","doi-asserted-by":"crossref","unstructured":"Saussele S, Lauseker M, Gratwohl A, et al.: Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880\u20135","DOI":"10.1182\/blood-2009-08-237115"},{"key":"10.3238\/arztebl.2015.0262_ref10","doi-asserted-by":"crossref","unstructured":"Stelljes M, Krug U, Beelen DW, et al.: Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288\u201396","DOI":"10.1200\/JCO.2013.50.5768"},{"key":"10.3238\/arztebl.2015.0262_ref11","doi-asserted-by":"crossref","unstructured":"Kroger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264\u201370","DOI":"10.1182\/blood-2009-07-234880"},{"key":"10.3238\/arztebl.2015.0262_ref12","doi-asserted-by":"crossref","unstructured":"Khoury HJ, Kukreja M, Goldman JM, et al.: Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012; 47: 810\u20136","DOI":"10.1038\/bmt.2011.194"},{"key":"10.3238\/arztebl.2015.0262_ref13","doi-asserted-by":"crossref","unstructured":"Crawley C, Szydlo R, Lalancette M, et al.: Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969\u201376","DOI":"10.1182\/blood-2004-09-3544"},{"key":"10.3238\/arztebl.2015.0262_ref14","doi-asserted-by":"crossref","unstructured":"Barbui T, Barosi G, Birgegard G, et al.: Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761\u201370","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"10.3238\/arztebl.2015.0262_ref15","doi-asserted-by":"crossref","unstructured":"Passamonti F, Rumi E, Pungolino E, et al.: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755\u201361","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"10.3238\/arztebl.2015.0262_ref16","doi-asserted-by":"crossref","unstructured":"Gangat N, Caramazza D, Vaidya R, et al.: DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u20137","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"10.3238\/arztebl.2015.0262_ref17","doi-asserted-by":"crossref","unstructured":"Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895\u2013901","DOI":"10.1182\/blood-2008-07-170449"},{"key":"10.3238\/arztebl.2015.0262_ref18","doi-asserted-by":"crossref","unstructured":"Scott BL, Gooley TA, Sorror ML, et al.: The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657\u201364","DOI":"10.1182\/blood-2011-08-372904"},{"key":"10.3238\/arztebl.2015.0262_ref19","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Biamonte F, Rotunno G, et al.: Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014; 123: 2157\u201360","DOI":"10.1182\/blood-2013-11-536557"},{"key":"10.3238\/arztebl.2015.0262_ref20","doi-asserted-by":"crossref","unstructured":"Bjorkholm M, Derolf AR, Hultcrantz M, et al.: Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410\u20135","DOI":"10.1200\/JCO.2011.34.7542"},{"key":"10.3238\/arztebl.2015.0262_ref21","doi-asserted-by":"crossref","unstructured":"Kennedy JA, Atenafu EG, Messner HA, et al.: Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121: 2725\u201333","DOI":"10.1182\/blood-2012-10-464248"},{"key":"10.3238\/arztebl.2015.0262_ref22","doi-asserted-by":"crossref","unstructured":"Buchner T, Urbanitz D, Hiddemann W, et al.: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583\u20139","DOI":"10.1200\/JCO.1985.3.12.1583"},{"key":"10.3238\/arztebl.2015.0262_ref23","doi-asserted-by":"crossref","unstructured":"Dohner H, Estey EH, Amadori S, et al.: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453\u201374","DOI":"10.1182\/blood-2009-07-235358"},{"key":"10.3238\/arztebl.2015.0262_ref24","doi-asserted-by":"crossref","unstructured":"Klepin HD, Rao AV, Pardee TS: Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol 2014; 32: 2541\u201352","DOI":"10.1200\/JCO.2014.55.1564"},{"key":"10.3238\/arztebl.2015.0262_ref25","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, et al.: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579\u201390","DOI":"10.1038\/nrclinonc.2012.150"},{"key":"10.3238\/arztebl.2015.0262_ref26","doi-asserted-by":"crossref","unstructured":"Kronke J, Schlenk RF, Jensen KO, et al.: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29: 2709\u201316","DOI":"10.1200\/JCO.2011.35.0371"},{"key":"10.3238\/arztebl.2015.0262_ref27","doi-asserted-by":"crossref","unstructured":"Schmid C, Schleuning M, Ledderose G, et al.: Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675\u201387","DOI":"10.1200\/JCO.2005.07.061"},{"key":"10.3238\/arztebl.2015.0262_ref28","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al.: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454\u201365","DOI":"10.1182\/blood-2012-03-420489"},{"key":"10.3238\/arztebl.2015.0262_ref29","doi-asserted-by":"crossref","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, et al.: Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943\u201364","DOI":"10.1182\/blood-2013-03-492884"},{"key":"10.3238\/arztebl.2015.0262_ref30","doi-asserted-by":"crossref","unstructured":"Koreth J, Pidala J, Perez WS, et al.: Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662\u201370","DOI":"10.1200\/JCO.2012.46.8652"},{"key":"10.3238\/arztebl.2015.0262_ref31","doi-asserted-by":"crossref","unstructured":"Lim Z, Brand R, Martino R, et al.: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405\u201311","DOI":"10.1200\/JCO.2009.21.8073"},{"key":"10.3238\/arztebl.2015.0262_ref32","doi-asserted-by":"crossref","unstructured":"Itzykson R, Kosmider O, Renneville A, et al.: Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428\u201336","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"10.3238\/arztebl.2015.0262_ref33","doi-asserted-by":"crossref","unstructured":"Bacher U, Haferlach T, Schnittger S, et al.: Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153: 149\u201367","DOI":"10.1111\/j.1365-2141.2011.08631.x"},{"key":"10.3238\/arztebl.2015.0262_ref34","doi-asserted-by":"crossref","unstructured":"Gooley TA, Chien JW, Pergam SA, et al.: Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091\u2013101","DOI":"10.1056\/NEJMoa1004383"},{"key":"10.3238\/arztebl.2015.0262_ref35","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Stern M, Brand R, et al.: Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715\u201326","DOI":"10.1002\/cncr.24531"},{"key":"10.3238\/arztebl.2015.0262_ref36","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20139","DOI":"10.1182\/blood-2005-05-2004"},{"key":"10.3238\/arztebl.2015.0262_ref37","doi-asserted-by":"crossref","unstructured":"Birninger N, Bornhauser M, Schaich M, et al.: The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation\u2014investigation of potential limitations of the index. Biol Blood Marrow Transplant 2011; 17: 1822\u201332","DOI":"10.1016\/j.bbmt.2011.06.009"},{"key":"10.3238\/arztebl.2015.0262_ref38","doi-asserted-by":"crossref","unstructured":"Pidala J, Lee SJ, Ahn KW, et al.: Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood 2014; 124: 2596\u2013606","DOI":"10.1182\/blood-2014-05-576041"},{"key":"10.3238\/arztebl.2015.0262_ref39","doi-asserted-by":"crossref","unstructured":"Schlenk RF, Dohner K, Mack S, et al.: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 4642\u20138","DOI":"10.1200\/JCO.2010.28.6856"},{"key":"10.3238\/arztebl.2015.0262_ref40","doi-asserted-by":"crossref","unstructured":"Kanakry CG, O\u2019Donnell PV, Furlong T, et al.: Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32: 3497\u2013505","DOI":"10.1200\/JCO.2013.54.0625"},{"key":"10.3238\/arztebl.2015.0262_ref41","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Ballen K, Rizzo D, et al.: Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628\u201333","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"10.3238\/arztebl.2015.0262_ref42","unstructured":"Zentrales Knochenmarkspende-Register Deutschland. www.zkrd.de (last accessed on 3 December 2014)"},{"key":"10.3238\/arztebl.2015.0262_ref43","doi-asserted-by":"crossref","unstructured":"Fabarius A, Leitner A, Hochhaus A, et al.: Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760\u20138","DOI":"10.1182\/blood-2011-08-373902"},{"key":"10.3238\/arztebl.2015.0262_ref44","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Breems D, van Putten WL, et al.: Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012; 30: 2140\u20136","DOI":"10.1200\/JCO.2011.39.6499"},{"key":"10.3238\/arztebl.2015.0262_ref45","doi-asserted-by":"crossref","unstructured":"Bornhauser M, Kienast J, Trenschel R, et al.: Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035\u201344","DOI":"10.1016\/S1470-2045(12)70349-2"},{"key":"10.3238\/arztebl.2015.0262_ref46","doi-asserted-by":"crossref","unstructured":"Kurosawa S, Yamaguchi T, Uchida N, et al.: Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011; 17: 401\u201311","DOI":"10.1016\/j.bbmt.2010.07.013"},{"key":"10.3238\/arztebl.2015.0262_ref47","doi-asserted-by":"crossref","unstructured":"Lussana F, Rambaldi A, Finazzi MC, et al.: Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014; 99: 916\u201321","DOI":"10.3324\/haematol.2013.094284"},{"key":"10.3238\/arztebl.2015.0262_ref48","doi-asserted-by":"crossref","unstructured":"Jiang Q, Xu LP, Liu DH, et al.: Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032\u201340","DOI":"10.1182\/blood-2010-09-308510"},{"key":"10.3238\/arztebl.2015.0262_ref49","doi-asserted-by":"crossref","unstructured":"Germing U, Kobbe G, Haas R, et al.: Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 2013; 110: 783\u201390","DOI":"10.3238\/arztebl.2013.0783"},{"key":"10.3238\/arztebl.2015.0262_ref50","doi-asserted-by":"crossref","unstructured":"Alchalby H, Zabelina T, Stubig T, et al.: Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20: 279\u201381","DOI":"10.1016\/j.bbmt.2013.10.027"},{"key":"10.3238\/arztebl.2015.0262_ref51","doi-asserted-by":"crossref","unstructured":"Koreth J, Schlenk R, Kopecky KJ, et al.: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349\u201361","DOI":"10.1001\/jama.2009.813"},{"key":"10.3238\/arztebl.2015.0262_ref52","doi-asserted-by":"crossref","unstructured":"Jenq RR, van den Brink MR: Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213\u201321","DOI":"10.1038\/nrc2804"},{"key":"10.3238\/arztebl.2015.0262_ref53","doi-asserted-by":"crossref","unstructured":"Fuchs EJ: Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program 2012; 2012: 230\u20136","DOI":"10.1182\/asheducation.V2012.1.230.3798312"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:33:41Z","timestamp":1638779621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0262","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/978-3-319-33198-0_12","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,10]]}}}